NOVEL DETECTION METHODOLOGY FOR LYME DISEASE TARGETS

Information

  • Research Project
  • 2005845
  • ApplicationId
    2005845
  • Core Project Number
    R43AI041316
  • Full Project Number
    1R43AI041316-01
  • Serial Number
    41316
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/1997 - 27 years ago
  • Project End Date
    11/30/1997 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    3/1/1997 - 27 years ago
  • Budget End Date
    11/30/1997 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/21/1997 - 27 years ago
Organizations

NOVEL DETECTION METHODOLOGY FOR LYME DISEASE TARGETS

Early, definitive detection of pathogenic agents often is key to effective treatment and full recovery. Although DNA and protein-based detection systems are widely used to detect pathogen and disease markers, a number of systems have limited capacity to rapidly produce reagents specific for existing and emerging new pathogens. The overall goal of the proposed research is to develop a general, non- immunological method to rapidly obtain reagents with high affinity and specificity for detecting protein targets. The approach is based on a recombinant display library that uses biotin carboxylase carrier protein (BCCP) as a scaffold. In Phase I, methods will be developed to assay and combine individual isolates obtained from this library to create bispecific detection complexes. The membrane protein antigen BmpC of Borellia burgdorferi, the causative agent of Lyme disease, will serve as the initial target, and will provide a model for obtaining reagents specific to other pathogens. Phase II studies will apply the technology to obtain bispecific reagents for other targets, incorporate the bispecifics into existing assay formats and test assay effectiveness in clinical samples. Phase III will involve final process development, incorporation into automated diagnostic systems, and application in commercial markets via partnerships with private pharmaceutical diagnostics firms. PROPOSED COMMERCIAL APPLICATION: Anticipated commercial applications include new confirmatory diagnostic systems with greatly improved specificity and instrument compatibility, new detection reagents for research and clinical applications, and new manufacturing processes for licensing. Research product applications will be commercialized through Promega's own network; clinical product applications will be commercialized through a pharmaceutical partner. Commercially, Lyme disease is an excellent initial target since it is the most common arthropod-borne disease in the United States, with more than 10,000 new cases occurring in the U.S. each year.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    PROMEGA CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    MADISON
  • Organization State
    WI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    537115399
  • Organization District
    UNITED STATES